Featured Products

• Netarsudil(Mesylate) (Catalog# : 712181, Cas# : 1422144-42-0) NEWNetarsudil, also known as AR-11324, is a Rho-associated protein kinase inhibitor. Netarsudil is potential useful for treating glaucoma and​/or reducing intraocular pressure. Neta
• Entrectinib(RXDX-101) (Catalog# : 100504, Cas# : 1108743-60-7) Entrectinib (RXDX-101) is a selective inhibitor for all three TRK receptor tyrosine kinases encoded by the three NTRK genes, as well as the ROS1 and ALK receptor tyrosine kinases.
• JPH203 HCl (Catalog# : 18381, Cas# : 1597402-27-1) JPH203, also known as KYT-0353, is a potent and selective LAT1 selective ( L-type amino acid transporter 1) inhibitor. JPH203 can very potently inhibit l-leucine uptake.
• lumateperone(Tosylate) (Catalog# : 17012102, Cas# : 1187020-80-9) Lumateperone (ITI-722/ITI-007) is a novel, first-in-class dual 5HT2A receptor antagonist/dopamine phosphoprotein modulator (DPPM) for schizophrenia. It is an orally available com
• SCR7 pyrazine (Catalog# : 1712261, Cas# : 14892-97-8) NEWSCR7 pyrazine is a small molecule inhibitor of DNA ligase IV that prevents nonhomologous end-joining by interfering with ligase binding and activating apoptosis.
• eCF506 (Catalog# : 18382, Cas# : 1914078-41-3) eCF506 targets a molecule called Src tyrosine kinase that is required for breast cancer cells to grow and spread. eCF506 may be highly effective at blocking growth of breast canc
• Esaxerenone (Catalog# : 1710121, Cas# : 1632006-28-0) Esaxerenone (INN) (developmental code names CS-3150, XL-550) is a nonsteroidal antimineralocorticoid which was discovered by Exelixis and is now under development by Daiichi Sank
• Copanlisib HCI (Catalog# : 18351, Cas# : 1402152-13-9) Copanlisib also known as BAY 80-6946, is a potent phosphoinositide 3-kinase (PI3K) inhibitor. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result i
• Cenicriviroc (Catalog# : 179139, Cas# : 497223-25-3) Cenicriviroc (code names TAK-652, TBR-652) is an experimental drug candidate for the treatment of HIV infection.
• WWL70 (Catalog# : 16122847, Cas# : 947669-91-2) WWL70 is selective ABHD6 inhibitor, and it has shown anti-inflammatory and neuroprotective effects in animal models of traumatic brain injury and multiple sclerosis.
• VU0467154 (Catalog# : 18576, Cas# : 1451993-15-9) NEWVU0467154 is a potent and selective M4 PAM.
• KI-696 (Catalog# : 1710132, Cas# : 1799974-70-1) KI-696 represents an excellent LMW tool to study the KEAP1-NRF2 interaction in vivo. Discovered by FBS, the probe is well characterised in a number of in vitro assays as well as
• L-778123 (Catalog# : 1711249, Cas# : 183499-57-2) L-778,123 is an inhibitor of FPTase and GGPTase-I.
• ABT-100 (Catalog# : 1710131, Cas# : 450839-40-4) ABT-100 is an orally bioavailable farnesyltransferase inhibitor.
• Pemafibrate (Catalog# : 179221, Cas# : 848259-27-8) NEW(1)Pemafibrate, also known as K-877 and (R)-K 13675, is a PPAR alpha agonist. (R)-K-13675 decreases the secretion of inflammatory markers without affecting cell proliferation or
• IU1 (Catalog# : 51637, Cas# : 314245-33-5) IU1 is a reversible and specific inhibitor of proteasome-associating Usp14. It does not inhibit other deubiquitinating enzymes of the 26S proteasome. It partially inhibits the ub
• Cobicistat(GS-9350) (Catalog# : 51906, Cas# : 1004316-88-4) Cobicistat is a potent inhibitor of cytochrome P450 3A enzymes, including the important CYP3A4 subtype. It also inhibits intestinal transport proteins, increasing the overall abs
• CPI-613 (Catalog# : 51905, Cas# : 95809-78-2) CPI-613 is an E1 pyruvate dehydrogenase (PDH) modulator that prevents cancer cells from metabolizing glucose for energy. CPI-613 has been granted orphan drug status by the US FD
• CX-4945(Silmitasertib) (Catalog# : 52024, Cas# : 1009820-21-6) CX-4945 (Silmitasertib) is a potent and selective inhibitor of CK2 (casein kinase 2) with IC50 of 1 nM, less potent to Flt3, Pim1 and CDK1 (inactive in cell-based assay).  
• SRT1720 (Catalog# : 52007, Cas# : 1001645-58-4(HCl);925434-55-5(free base)) SRT1720 is a selectiveSIRT1activator withEC50of 0.16 M, but is >230-fold less potent for SIRT2 and SIRT3. SRT1720(SRT-1720) is an experimental drug that was studied by Sirtris
• MORE  >>